OpGen WKN: A2PQ6B ISIN: US68373L3078 Forum: Aktien Thema: Hauptdiskussion

Uhhh

9.6. Hauptversammlung

@Pennyzock Jedoch sind die Aktien der Aktienerhöhung nicht sofort handelbar, ich meine es ist mindestens ein lock-up von 6 Monaten, oder?

Quartalszahlen 1.Quartal 2022 https://ir-opgen-com.translate.goog/news-releases/news-release-details/opgen-reports-first-quarter-2022-financial-results-and-provides?_x_tr_sl=en&_x_tr_tl=de&_x_tr_hl=de&_x_tr_pto=sc

Weil Oliver nach dem reversed split sofort wieder eine Aktien erhöhung durch die Ausgabe neuer Aktien Das ist ein wenig ungerecht.

Die Frage ist wie stark es steigt bei einem reverse split und was die shorter dann machen. Kann auch explodieren

Warum verkaufen wenn ein reverse split ansteht? Das macht keinen sinn.

Am 12 Mai gibt es die Q1 Zahlen.

https://www.reddit.com/r/StockMarket/comments/u8mwuz/opgn_fighting_the_next_pandemic/?utm_source=share&utm_medium=ios_app&utm_name=iossmf

Aus einem reddit-Artikel der allerdings mittlerweile entfernt wurde https://www.reddit.com/r/StocksAndTrading/comments/u8pfu7/opgn_development_of_molecular_information/?utm_source=share&utm_medium=ios_app&utm_name=iossmf OPGN / development of molecular information products and services for global healthcare settings $OPGN I highly recommend anyone who has doubts about the authenticity of these messages to search Google for the collaboration between the OPGEN company Curetis and the other companies involved Curetis, Contexo and Ares Genetics. These companies have found each other very well in recent years. Since 2012, immense development work has been carried out in the machine for the decentralized detection of specific MRSA germs on site. That will pay off now. So I took a closer look at the people behind the companies ARES, CURETIS and OPGEN. They really mean it! The supplier for the automatic mini-laboratory that detects pneumonia pathogens is called Contexo. They already expanded their production capacities last year. In the USA, Curetis has received approval for a test that can diagnose more than 30 different pathogens causing severe pneumonia and can also identify a number of markers for resistance. According to estimates by Curetis, around one million patients in Europe and the USA are affected by such infections. Comparable diagnostics for these cases are, according to Schacht, not yet on the market. The young German biotech company Curetis (OPGEN) wants to close this gap with its "Unyvero" system for faster infection diagnosis. The company has now also received US FDA approval for this platform, which has already been marketed in the US and Europe. OpGen is hopefully receiving Chinese NMPA approval for the Curetis Unyvero system. https://www.bioregio-stern.de/en/database/company/curetis-gmbh The Unyvero A50 System is a rapid molecular diagnostics platform used for reliable and accurate diagnosis of severe infectious diseases. The system uses powerful multiplex PCR technology to detect a wide variety of microorganisms, antibiotic resistance markers, or toxins from sample-to-answer within 4-5 hours. Growing revenue from Unyvero product sales in the U.S. and globally as well as growth of the Ares Genetics services and data access business were key drivers of the 2021 revenue generation. https://clinicaltrials.gov/ct2/show/NCT03711331?term=Curetis&draw=2&rank=3 https://www.mcknights.com/marketplace/marketplace-experts/best-practices-for-antibiotic-stewardship-infection-control-in-long-term-care/ https://technical.ly/startups/opgen-fda-gene-panel/ OPGEN made a stroke of luck with the takeover of CURETIS and $ARES . Both have a direct line to the Chinese company BGI, which has not only developed the PCR-based rapid test, but also a sequencing platform with which any changes in viruses can be determined and tracked. In this cooperation, new solutions for the detection of infectious diseases are found on the basis of next-generation sequencing (NGS). After all, BGI has determined the sequence of the virus variant and enjoys the full support of the state authorities in China. Ares Genetics Antibiotics are one of the most important weapons in fighting bacterial infections. However, the increased use has often led to antibiotic resistance in recent years and makes it increasingly difficult for medical professionals to treat patients effectively. This is where the digital diagnostics startup Ares Genetics, founded in 2017, comes in. It wants to improve testing for antibiotic resistance and diagnostics in the health sector: “Traditional laboratory tests usually take a few days to weeks to determine antibiotic resistance. You take a sample from the patient, cultivate it, add an antibiotic and analyze whether bacteria are growing or not.

Die Ausnahme war Aurora Cannabis mit reverseSplit von 12:1, als die Aktie plötzlich 8€ Wert war haben viele Newcomer gedacht, „jetzt geht’s hier richtig ab“ in 2019/2020.

Naja lassen wir uns mal überraschen...bis jetzt war hier irgendwie alles eine Enttäuschung :/

CEO hat nachgekauft und Reverse Splitt vor haben , verarsche suchen doofe Europäer

Gute Erfahrungen hab ich mir einen Split auch selten gemacht....meist startet dann ein neuer Abverkauf..